Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;88(5):3031-8.
doi: 10.1128/JVI.03333-13. Epub 2013 Dec 18.

Epigenetic regulation of HIV-1 latency in astrocytes

Affiliations

Epigenetic regulation of HIV-1 latency in astrocytes

Srinivas D Narasipura et al. J Virol. 2014 Mar.

Abstract

HIV infiltrates the brain at early times postinfection and remains latent within astrocytes and macrophages. Because astrocytes are the most abundant cell type in the brain, we evaluated epigenetic regulation of HIV latency in astrocytes. We have shown that class I histone deacetylases (HDACs) and a lysine-specific histone methyltransferase, SU(VAR)3-9, play a significant role in silencing of HIV transcription in astrocytes. Our studies add to a growing body of evidence demonstrating that astrocytes are a reservoir for HIV.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(a) Reactivation of HIV mRNAs in astrocytes. PDAs were infected with HIVBal (10 ng/ml/106 cells) and left untreated (UT) or treated with PHA (4 μg/ml) or TNF-α (TNFa) (100 U/ml), and HIV mRNAs were measured by qRT-PCR. Data are normalized to GAPDH mRNA and expressed as fold change relative to results for untreated cells. Asterisks denote P < 0.05 between results for treated and untreated cultures. (b) Inducible and low level of HIV replication in astrocytes is transmitted to lymphocytes. Astrocytes were primed with IFN-γ (75 U/ml) or left untreated and then infected with HIVBal (10 ng/ml/106 cells) and cultured with or without IFN-γ (IFNg). The initial virus inoculum was removed by mild pronase treatment and washing; the supernatant was harvested from astrocytes at day 7 postinfection and then exposed to anti-CD3/anti-CD28-costimulated PBMCs. HIV p24 from PBMC supernatant was measured by ELISA on day 6. HIV mRNA (Env) from PBMCs was quantified by real-time PCR on day 6, normalized to GAPDH, and presented as expression relative to that for uninfected cultures. HIV p24 from IFN-γ/HIV or HIV+ cultures was undetectable. *, P < 0.05 (Student's t test) between results for control and treated samples.
FIG 2
FIG 2
Estimation of frequency of HIV infection in astrocytes: a standard curve was generated to determine the percentage of infected cells based on use of a mixture of DNA from U1 (contains 2 proviral copies/cell) and U937 (U1 parental cell line). HIVBal (10 ng/ml/106 cells) was used to infect stimulated PBMCs, primary astrocytes (PDA), or an astrocytic cell line (U138). HIV DNA was amplified using Alu-PCR followed by real-time PCR. Linear regression list dotted line and standard curve are shown.
FIG 3
FIG 3
Transcript and protein expression profiles of HDACs in astrocytes. (a) RNA extracts (1 μg) from PDAs were subjected to real-time PCR to detect and quantify all of the 11 HDACs and CCDN1. GAPDH was used as an internal control, and data are presented as fold change relative to results for CCDN1. (b and c) Protein extracts (20 μg each) from PDAs (b) or U87MG (c) were used to perform Western blot analysis using antibodies specific to HDAC1, -2, -3, and -4 from an HDAC antibody sampling kit (Cell Signaling) or GAPDH. *, P < 0.05 (Student's t test) between results for CCDN1 and HDAC2.
FIG 4
FIG 4
HDAC class 1 inhibitors significantly induce HIV LTR activity in astrocytes: U87MG cells with stably integrated HIV LTR-Luc were treated with various concentrations of HDAC inhibitors having selective specificity as indicated in Table 1. The agents were SAHA (a), apicidin (b),TSA (c), VAHA (d), MC1568 (e), salermide (f), splitomicin (g), or 1-naphthohydroxamic acid (h). Approximately 24 h posttreatment, cells were lysed and measured for luciferase activity. The data are normalized to total protein content and presented as fold change with respect to results for DMSO-treated cells ± SD. *, P < 0.05 (Student's t test) between results for DMSO-treated and drug-treated samples.
FIG 5
FIG 5
Induction of stable LTR activity is specific to trimethylation of histone H3 at Lys9 (H3K9me3). LTR-Luc-stably integrated U87MG cells were treated with AZA, a DNMT inhibitor (a), garcinol, a potent HAT inhibitor (b), UNC0638, GLP (H3K9 monomethyltransferase) and G9a (H3K9 dimethyltransferase) inhibitor (c), BIX0124, a specific G9a inhibitor (d), or chaetocin, a specific inhibitor of SU(VAR)3–9, an H3K9 trimethyltransferase (e), at the concentrations indicated. Approximately 24 h posttreatment, the cells were lysed and assayed for luciferase activity, normalized to total protein content. Data are presented as fold change with respect to results for DMSO-treated cells ± SD. *, P < 0.05 (Student's t test) between DMSO-treated and drug-treated samples.
FIG 6
FIG 6
SAHA, apicidin, and chaetocin strongly induce HIV transcripts and infectious virus from PDAs and U138MG astrocytes. PDAs (a) or U138MG cells (b) were infected with HIVBal and treated with SAHA (10 μM), apicidin (1 μg/ml), chaetocin (200 nm), or vehicle control. RNA was isolated 24 h posttreatment, 1 μg reverse transcribed to cDNA, and subjected to real-time PCR to quantify HIV Gag, Env, and Rev (c) transcripts. Data are normalized to results for GAPDH and are represented as fold change with respect to results for control (DMSO)-treated cells ± SD. (d) Supernatants from SAHA-, chaetocin-, or DMSO-treated HIVBal-infected PDAs were added to anti-CD3/anti-CD28-activated PBMCs. At day 6, HIV transcript (Env) from PBMCs was quantified by real-time PCR. Data are normalized to results for GAPDH and are represented as fold change with respect to results for control-treated samples. *, P < 0.05 (Student's t test) between results for control (DMSO)-treated and inhibitor-treated samples.

Similar articles

Cited by

References

    1. Le Douce V, Janossy A, Hallay H, Ali S, Riclet R, Rohr O, Schwartz C. 2012. Achieving a cure for HIV infection: do we have reasons to be optimistic? J. Antimicrob. Chemother. 67:1063–1074. 10.1093/jac/dkr599 - DOI - PMC - PubMed
    1. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 106:9403–9408. 10.1073/pnas.0903107106 - DOI - PMC - PubMed
    1. Schnell G, Price RW, Swanstrom R, Spudich S. 2010. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J. Virol. 84:2395–2407. 10.1128/JVI.01863-09 - DOI - PMC - PubMed
    1. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. 2011. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 7:e1002286. 10.1371/journal.ppat.1002286 - DOI - PMC - PubMed
    1. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. 2009. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 5:e1000395. 10.1371/journal.ppat.1000395 - DOI - PMC - PubMed

Publication types

MeSH terms